Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076238 · ClinicalTrials.gov registry record
Biomarkers of Phage Treatment Response in NTM and Other Infections
A clinical trial of Nontuberculous Mycobacterial Lung Disease, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07076238: Recruiting study of Nontuberculous Mycobacterial Lung Disease, sponsored by NYU Langone Health.
NCT07076238 is a study of Nontuberculous Mycobacterial Lung Disease that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076238, a study of Nontuberculous Mycobacterial Lung Disease, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to identify biomarkers associated with response to phage therapy for refractory bacterial infections. This includes mycobacteriophage treatment for patients with nontuberculous mycobacterial infections. Blood and airway samples will be obtained from follow up visits of patients with refractory bacterial infections that are considered for phage therapy. Samples will be compared between those that receive phage therapy and those that did not. Biomarkers will include changes in the airway microbiome, transcriptome, inflammatory cytokines, and development of neutralizing antibody against phages. The primary endpoint is to identify biomarkers associated with clinical and/or radiographic improvement and/or culture improvement which includes clearing of cultures or decrease in qualitative or resolution of signs and symptoms of infection after at least 6-8 weeks of bacteriophage therapy.
Primary Outcome
Improvement includes clearing of cultures or decrease in qualitative or resolution of signs and symptoms of infection after at least 6-8 weeks of bacteriophage therapy.
Conditions Studied
Interventions
- BIOLOGICAL Bacteriophage Treatment
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2032-06-25 |
What NCT07076238 shows while recruiting
NCT07076238 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Nontuberculous Mycobacterial Lung Disease appearing as the primary indexed condition, and to 1 intervention - of which Bacteriophage Treatment is the first listed.
NCT07076238 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07076238 about?
NCT07076238 is a clinical study titled "Biomarkers of Phage Treatment Response in NTM and Other Infections". This study aims to identify biomarkers associated with response to phage therapy for refractory bacterial infections. This includes mycobacteriophage treatment for patients with nontuberculous mycobacterial infections. Blood and airway samples will be obtained from follow up visits of patients with ...
What is the current status of trial NCT07076238?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-06-25. Estimated completion is 2032-06-25.
What conditions does trial NCT07076238 study?
This clinical trial studies the following conditions: Nontuberculous Mycobacterial Lung Disease.
What interventions are being tested in trial NCT07076238?
The interventions under investigation include: Bacteriophage Treatment (BIOLOGICAL).
Who is sponsoring clinical trial NCT07076238?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076238 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nontuberculous Mycobacterial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI